What Centre Oscar Lambret does

Centre Oscar Lambret is a private non-profit regional cancer center founded in 1955 and headquartered in Lille, France, operating as a Centre de Lutte Contre le Cancer within the UNICANCER federation of 18 French non-profit cancer centers (member since 2011). It provides comprehensive oncology services spanning radiotherapy, surgery, chemotherapy, immunotherapy, supportive care, palliative care, and genetic predisposition assessment for adult, pediatric, adolescent, and young adult patients across the Hauts-de-France region, with ~600 pediatric and ~950 gynecological cancer cases treated annually and 82% patient satisfaction versus a 73.3% national average.

Its technology backbone includes two Halcyon radiotherapy systems, a CyberKnife stereotactic radiosurgery unit (first north of Paris), three Tomotherapy units, a da Vinci Xi dual-console surgical robot (€2.8M investment), and Prosigna genomic testing (only facility in Hauts-de-France offering it), supported by a new €14.7M radiotherapy facility inaugurated in February 2020 with a shared 1.5T MRI and CT scanner. Digital infrastructure comprises the MonOscar patient portal with telemedicine capabilities, an Avatar Kids NAO robot telepresence pilot, and virtual reality for pain management. Clinical research is anchored in CLIP2 Lille (the only early-phase trials center in Hauts-de-France), 174 active studies in 2017 (42 promoted), and the UTRT translational research unit.

The business model combines public reimbursement under France's conventional tariff system (zero patient cost-sharing, no fee overruns) with donations and legacies channeled through the Service Relation Donateurs. Income is generated from national health insurance reimbursement for procedures, hospitalizations, radiotherapy, and surgery, supplemented by individual and corporate donations (€50-€150 one-time, €10-€30 monthly) eligible for 66% French tax credit. Referral flows originate from regional hospitals and physicians across Hauts-de-France, with dedicated international patient services for foreign patients. Recognitions include the 2026 OECI Comprehensive Cancer Center accreditation (first in Hauts-de-France), 2018 HAS Haute Qualité des soins certification, 2017 ISO 9001:2015 clinical research certification (first in region), and ESGO ovarian cancer surgery certification.

Name

Centre Oscar Lambret

Legal name

Centre Oscar Lambret

Website

https://centreoscarlambret.fr

Company type

Private

Founded year

1955

Operating status

Operating

Headcount range

251–500 employees

Short description

Centre Oscar Lambret is a private non-profit regional cancer center in Lille, France, operating within the UNICANCER federation. It delivers comprehensive oncology care, including radiotherapy, robotic surgery, chemotherapy, clinical trials, and translational research to patients across the Hauts-de-France region.

Ownership category

akta.pro rank

Product category

Comprehensive Cancer Center Services

NAICS

Medical and Diagnostic Laboratories (62151), Diagnostic Imaging Centers (621512), Medical and Diagnostic Laboratories (6215)

SIC

Services-General Medical & Surgical Hospitals, Nec (8062)

akta.pro primary industry

Oncology & Cancer Specialty Hospitals (HLAFAHAC)

akta.pro secondary industries

Ambulatory Oncology Centers (Outpatient Chemo/Radiation) (HLAFABAI), Gynecologic Oncology & Women’s Cancer Centers (HLAFAJAK), Breast Oncology (HLAKAFAJ), Thoracic (Lung) Oncology (HLAKAFAL)

Keywords

• Cancer treatment services
• Radiotherapy oncology
• Clinical cancer research
• Surgical oncology care
• Pediatric oncology center

Headquarters

HQ city

Lille

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

1. Healthcare Service Delivery: Centre Oscar Lambret is a private non-profit healthcare establishment exclusively dedicated to cancer care, research, and higher education. It participates in the public hospital service with conventional tariffs, providing care without patient cost-sharing (no reste à charge) and without fee overruns (dépassement d'honoraires). Revenue is generated through national health insurance reimbursement for medical procedures, radiotherapy, chemotherapy, surgery, and hospitalizations.
2. Donations and Legacies: The center actively solicits donations from individuals and organizations to fund research projects, pediatric unit improvements, and innovative equipment. Donation campaigns include one-time and monthly giving options, with tax deduction benefits for French donors.

Pricing tiers

Distribution channels4 records

Marketing channels8 records

Core offering

Centre Oscar Lambret is a private non-profit comprehensive cancer center providing full-spectrum oncology care (radiotherapy, chemotherapy, surgery, immunotherapy, supportive and palliative care), clinical and translational research (including Phase I/II early-phase trials), higher education through its IFOL training institute, and dedicated pediatric and breast cancer programs. It participates in the French public hospital service under conventional tariffs with no patient cost-sharing and no fee overruns, operating advanced technologies including Halcyon, CyberKnife, da Vinci Xi robotics, and Prosigna genomic testing.

Product overview

Centre Oscar Lambret is a regional cancer center in Lille, France, and a member of the UNICANCER federation. It operates as a unified healthcare institution offering a comprehensive, integrated cancer care model spanning treatment, research, and education. The portfolio includes the core patient care services (medical and surgical oncology, radiotherapy, imaging), the MonOscar digital patient portal for telemedicine and secure medical communication, the Institut de Formation Oscar Lambret (IFOL) for professional healthcare training, and the translational research unit (UTRT). Specialized branded programs include the Parcours Rose breast cancer pathway, the Centre de Santé du Sein multidisciplinary breast center, and public awareness campaigns such as Septembre en Or (pediatric cancers), October Rose/Parcours Rose, and Les Moustaches d'Oscar (male cancers). Technical infrastructure includes advanced robotic surgery (da Vinci Xi®), radiotherapy platforms (Halcyon™, CyberKnife®, Tomotherapy), and telepresence solutions (Avatar Kids).

Differentiator

Problem solved

Functional benefit

Brands

• MonOscar: Personalized patient digital space and telemedicine platform enabling patients to access their medical information and communicate with healthcare providers.
• IFOL (Institut de Formation Oscar Lambret)

Products and services

• Comprehensive Oncology Treatment Services Full-spectrum cancer treatment including radiotherapy (Halcyon, CyberKnife, tomotherapy), chemotherapy, immunotherapy, robotic-assisted and conventional surgery, and supportive/palliative care delivered to adult and pediatric oncology patients in Hauts-de-France under the French public hospital service framework with no out-of-pocket costs.
• MonOscar Digital Patient Portal Personalized, secure digital platform enabling patients and healthcare professionals to exchange medical information, schedule appointments, access medical records, and conduct telemedicine consultations, with mobile app support.
• Parcours Rose Breast Cancer Pathway Streamlined breast cancer care pathway where patients meet all multidisciplinary care providers (surgeon, anesthesiologist, radiologist, ambulatory surgery nurse) in a single half-day session, reducing logistical burden and anxiety.
• Centre de Santé du Sein (Breast Health Center) Dedicated breast health center providing a multidisciplinary optimized pathway for all women with breast abnormalities, including oncogenetics, Prosigna genomic testing, and breast reconstruction consultations.
• Institut de Formation Oscar Lambret (IFOL) Professional training institute offering continuing education for healthcare professionals in oncology, with a catalog of courses, seminars, and certifications; ANDPC registration N°1061, supported by 78 internal and 22 external trainers.
• Translational Research Unit (UTRT) Translational research unit on tumorigenesis and treatment resistance conducting research projects to advance understanding and treatment of cancer, with findings feeding back into clinical practice.
• Clinical Trials and Early-Phase Studies (CLIP2 Lille) Clinical research program offering 174+ open studies including Phase I/II early-phase trials through CLIP2 Lille, the only early-phase clinical trials center in Hauts-de-France, with ISO 9001:2015 certification for all clinical research activities.
• Pediatric Oncology Program Specialized pediatric, adolescent, and young adult (AYA) oncology program treating approximately 600 patients per year, including the Avatar Kids telepresence program using the NAO humanoid robot to enable hospitalized children to maintain school continuity.
• Gynecological Oncology Program (ESGO-certified) Specialized gynecological cancer treatment (cervical, endometrial, ovarian) with ESGO-certified ovarian cancer surgery program treating 950 gynecological cancers per year, integrating minimally invasive surgery with the da Vinci Xi surgical robot.
• Robotic-Assisted Surgery (da Vinci Xi) Minimally invasive robotic-assisted cancer surgery using the da Vinci Xi dual-console system for gynecological, ENT (ORL), and digestive cancers, enabling complex procedures with reduced patient invasiveness.
• Advanced Radiotherapy Services Advanced radiotherapy treatment delivery using Halcyon systems, CyberKnife stereotactic radiosurgery, tomotherapy units, and an integrated MRI 1.5T and CT scanner facility for personalized radiation treatment planning and delivery.
• Prosigna Genomic Testing Service Genomic test revealing the genetic fingerprint of breast tumors to evaluate biological nature and recurrence risk, enabling personalized treatment planning for breast cancer patients.
• Oncogenetics and Cancer Predisposition Assessment Genetic predisposition and risk evaluation service for patients and families with hereditary cancer risk, including oncogenetic consultation and counseling for breast, ovarian, colorectal, and other hereditary cancers.
• Donation and Fundraising Program Philanthropic fundraising program accepting one-time donations (€50, €80, €100, €150, or custom) and monthly donations (€10, €15, €20, €30), with 66% French tax credit eligibility, supporting research, pediatric unit improvements, and innovative equipment.

Quantifiable outcome

• 82% patient satisfaction rate (vs 73.3% national average for healthcare facilities)
• +5 more outcomes

Named customers4 records

Segments9 records

Ideal customer profiles5 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature9 records

Partnerships

18 partnerships are on record, tiered minor, core, major and innovative.

• Access EthicsminorImplementation/ SI/ Consulting Partner · 1 January 2024Access Ethics conducted the RGAA 4.2 accessibility audit of the Centre's website, finding 80% mean compliance and 64% of RGAA criteria met.
• Pr Karim FizazicoreOthers · 1 January 2019Internationally renowned prostate cancer specialist recruited to lead the Centre's Medical and Scientific Project, accelerating innovation in male cancer care in Hauts-de-France.
• Laboratoire RocheminorGTM or Marketing Partner · 1 January 2019Roche laboratory partnered with the Centre during Mars Bleu colorectal cancer awareness campaign, providing sponsorship for the giant colon immersion experience and educational workshops.
• Lili Sohn (Illustrator)minorGTM or Marketing Partner · 1 January 2019Illustrator Lili Sohn, known for 'La guerre des tétons', partnered with the Centre for the 2019 Pink October '#LesSeinsEtLeDépistage' campaign, using humor to raise awareness about breast cancer screening.
• LOSC (Lille Olympique Sporting Club)minorGTM or Marketing Partner · 1 January 2019Lille OSC football club partnered with the Centre for the 2019 September en Or campaign, hosting a special match on September 14 to raise awareness for pediatric cancers.
• Pr Karim FizazicoreOthers · 1 January 2019Internationally recognized prostate cancer expert leading the Centre's Medical and Scientific Project, driving innovation in male cancer care and research in the Hauts-de-France region.
• CAMI Sport & CancermajorStrategic or Co-development Partner · 1 January 2019CAMI Sport & Cancer, in partnership with Malakoff Médéric and Laurette Fugain, worked with the Centre to develop the Sport & Cancer Pole, enabling patients to practice supported physical activity shown to reduce cancer recurrence risk and improve quality of life. This was the first such pole north of Paris.
• AudomaRoseminorGTM or Marketing Partner · 1 January 2019AudomaRose association, partner since two years, donated €30,000 in 2016 through concerts, motorcycle rides, hikes, and conferences organized during Pink October to support breast cancer research at the Centre.
• Fondation L'OréalmajorGTM or Marketing Partner · 1 January 2018L'Oréal Foundation partnered with UNICANCER to deploy an adapted onco-esthetics program across cancer centers in France. Experimented in 5 pilot centers before being progressively rolled out, including at Centre Oscar Lambret since September 2018. The program provides beauty and well-being care to patients experiencing treatment-related skin and body changes.
• Pr Karim FizazicoreOthers · 1 January 2018Recruited to lead the Centre's Medical and Scientific Project, bringing world-class expertise in prostate cancer and positioning the Centre as a regional leader in male cancer innovation.
• ERM RobotiqueinnovativeTechnology or Integration · 1 January 2017ERM Robotique partnered with the Centre to pilot the Avatar Kids telepresence project using the NAO humanoid robot, enabling hospitalized children to maintain school connections. Centre Oscar Lambret is the first pilot hospital in France for this initiative.
• GAEL (Groupement des Acteurs Economiques de Lille)minorGTM or Marketing Partner · 1 January 2017Business association GAEL, with support from the City of Lille, partnered with the Centre for Pink October breast cancer awareness, mobilizing regional business leaders.
• SantélyscoreStrategic or Co-development Partner · 1 January 2016Santélys, a regional healthcare network, partnered with the Centre to support the NEORASARC clinical trial for pre-operative radiotherapy in soft tissue sarcomas.
• Améliore La ViecoreStrategic or Co-development Partner · 1 January 2016Partner supporting the NEORASARC clinical trial evaluating a new pre-operative radiotherapy modality for soft tissue sarcomas.
• Lille By Mat'majorGTM or Marketing Partner · 1 January 2016Mathilde, blogger behind Lille By Mat', partnered with the Centre in 2016 and again in subsequent years to raise funds for the pediatric unit through the sale of the 'Sacrée Lilloise' agenda (€5 per agenda donated). In 2018 she supported the Flying Tiger campaign, helping raise €35,000.
• VAFC (Valenciennes Athletic Football Club)minorGTM or Marketing Partner · 1 January 2016VAFC football club partnered with the Centre for September en Or pediatric cancer awareness, organizing patient-kickoff at matches, stadium sensitization activities, and supporter-organized TIFO displays in gold September en Or colors.
• Flying Tiger CopenhagenmajorGTM or Marketing Partner · 1 January 2015Danish retailer Flying Tiger Copenhagen partnered with the Centre for annual Christmas solidarity campaigns. Since 2015, over €60,000 has been raised through the sale of solidarity products (unicorns, peacocks, bunny nightlights at €2-4 each with €2 donated per item) to fund the pediatric unit classroom and facilities. 18 stores in Hauts-de-France, Grand Est, and Nouvelle Aquitaine participated in 2019.
• UNICANCERcoreStrategic or Co-development Partner · 1 January 2011Centre Oscar Lambret has been a member of the UNICANCER federation since 2011. UNICANCER groups 18 private non-profit cancer centers in France. The federation coordinates clinical research, defines quality standards, advocates for the cancer sector, and supports the public hospital service mission with conventional tariffs and no patient cost-sharing.

Scale indicators14 records

Recent moves11 records

Expansion highlights6 records

Direct peers

• Institut Curie: Paris-based UNICANCER member combining a hospital and research center for cancer. Highly comparable model: private non-profit, research-driven oncology care, strong pediatric and women's cancer franchises, and integration of translational research.
• Gustave Roussy: France's leading comprehensive cancer center based in Villejuif, also a UNICANCER member. Directly comparable as a French non-profit academic cancer hospital delivering multi-modality oncology care, clinical trials, and translational research under a similar tariff model.
• Institut Paoli-Calmettes: Marseille-based UNICANCER cancer center with comparable scope across medical oncology, surgery, radiotherapy, early-phase trials, and translational research under the French public hospital service.
• Institut du Cancer de Montpellier (ICM): Montpellier-based UNICANCER comprehensive cancer center. Comparable as a French non-profit oncology hospital integrating care, research, and teaching under the same national framework.
• Centre Léon Bérard: Lyon-based UNICANCER comprehensive cancer center offering the same spectrum of surgery, radiotherapy, chemotherapy, and clinical trials. Same regulatory and tariff regime, providing a near-perfect regional peer for benchmarking.
• Institut de Cancérologie de l'Ouest (ICO): Western France UNICANCER cancer center with sites in Angers and Nantes. Directly comparable non-profit cancer hospital providing multi-site oncology care, trials, and research in a similar French tariff environment.

Broad incumbents

• Netherlands Cancer Institute (NKI): Dutch comprehensive cancer center combining hospital and research under one roof. Comparable as a European non-profit center with strong early-phase trial activity and similar multi-modality clinical offerings.
• The Institute of Cancer Research (ICR): UK-based research institute and partner of The Royal Marsden, focused on cancer research and treatment. Comparable as a European academic cancer center combining clinical trials, translational science, and patient care in a non-profit model.
• Charité – Universitätsmedizin Berlin (Comprehensive Cancer Center): Berlin's university hospital with a dedicated oncology center offering comparable multidisciplinary cancer care, trials, and translational research at significant European scale.

Others

• Varian (Siemens Healthineers): Vendor of Halcyon and other radiotherapy platforms used by Centre Oscar Lambret. Relevant as an enabling supplier whose technology roadmap and pricing directly affect the Centre's capex planning and clinical capabilities.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/centre-oscar-lambret

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Centre Oscar Lambret